Darolutamide is now an FDA-approved treatment option alone or in combination with docetaxel for metastatic ...

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free ...

Adding durvalumab to perioperative FLOT improved EFS in patients with resectable gastric or GEJ cancer in the MATTERHORN ...

Zejula with Zytiga and prednisone delayed cancer growth and symptoms in patients with castration-sensitive prostate cancer ...

BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster ...

Radium-223 in mCRPC showed long-term favorable safety, low second primary malignancies/fracture rates, and consistent overall ...

Patients with newly diagnosed gastric or gastroesophageal junction (GEJ) cancer who received the PD-L1 inhibitor durvalumab ...

Adding Enhertu to Perjeta improved time without cancer growth versus standard care in advanced HER2-positive breast cancer, ...

The results of this phase III KEYNOTE-991 study do not support the addition of pembrolizumab to enzalutamide and ADT for the treatment of mHSPC,” researchers wrote.

The FDA approved darolutamide monotherapy for use in metastatic hormone-sensitive prostate cancer following ARANOTE findings.

The FDA approved darolutamide (Nubeqa®) for metastatic castration-sensitive prostate cancer, based on the Phase III ARANOTE ...

CHICAGO -- Adding perioperative durvalumab (Imfinzi) to FLOT chemotherapy significantly improved event-free survival (EFS) ...